Paradigm Biocapital Advisors LP Vaxcyte, Inc. Transaction History
Paradigm Biocapital Advisors LP
- $2.14 Billion
- Q2 2025
A detailed history of Paradigm Biocapital Advisors LP transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Paradigm Biocapital Advisors LP holds 3,372,837 shares of PCVX stock, worth $109 Million. This represents 5.12% of its overall portfolio holdings.
Number of Shares
3,372,837
Previous 1,696,481
98.81%
Holding current value
$109 Million
Previous $64.1 Million
71.17%
% of portfolio
5.12%
Previous 3.28%
Shares
6 transactions
Others Institutions Holding PCVX
# of Institutions
324Shares Held
139MCall Options Held
229KPut Options Held
160K-
Janus Henderson Group PLC London, X014.7MShares$476 Million0.25% of portfolio
-
Vanguard Group Inc Valley Forge, PA12MShares$389 Million0.01% of portfolio
-
Ra Capital Management, L.P. Boston, MA12MShares$388 Million8.5% of portfolio
-
Black Rock Inc. New York, NY9.94MShares$322 Million0.02% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD6MShares$194 Million0.12% of portfolio
About Vaxcyte, Inc.
- Ticker PCVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,315,100
- Market Cap $1.92B
- Description
- Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...